Form 4: Helius Medical Technologies Director Receives Stock Options
SEC Form 4 Filing
Director Sherrie L Perkins receives stock options from Helius Medical Technologies, Inc.
Summary
- Sherrie L Perkins, a director of Helius Medical Technologies, Inc. (HSDT), received stock options on July 2, 2024.
- The options grant the right to buy 31,000 shares of Class A Common Stock at an exercise price of $0.965 per share.
- The options were granted under the Issuer's 2022 Equity Incentive Plan.
- The options vest in four equal quarterly installments starting September 30, 2024, contingent upon continued service.
Sentiment
Score: 6
Explanation: The document is a standard SEC filing related to stock option grants, which is generally neutral in sentiment. It reflects standard compensation practices.
Positives
- The grant of stock options aligns the director's interests with those of the shareholders, incentivizing performance and company growth.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize directors and key employees.
Stakeholder Impact
- The stock option grant could potentially dilute existing shareholders if the options are exercised.
Key Dates
| Date | Description |
|---|---|
| 07/02/2024 | Date of stock option grant |
| 09/30/2024 | First vesting date for the stock options |
| 07/01/2034 | Expiration date of the stock options |
Keywords
stock options, director, Helius Medical Technologies, HSDT, equity incentive plan, beneficial ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.